by Moteki, H. et al.
Department of Clinical Pharmacology, Faculty of Pharmaceutical Sciences, Josai University
Department of Clinical Pharmacology, Faculty of Pharmaceutical Sciences, Josai University
This EGF-induced ERK2 activation was abolished by treatment with the EGF-receptor kinase inhibitor AG1478 (10(-7) M) or the MEK (MAPK kinase) inhibitor PD98059 (10(-6) M).
Biol. Pharm. Bull. 2011; 10:1542-52